CRISPR Therapeutics

CRISPR Therapeutics is a biotechnology company that specializes in the development of transformative gene-based medicines using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA.

History

CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, one of the pioneers of the CRISPR/Cas9 technology. The company is headquartered in Zug, Switzerland, with operations in the United States.

Technology

CRISPR Therapeutics utilizes the CRISPR/Cas9 system, a technology that allows scientists to edit genes within organisms. The technology is considered a significant breakthrough in the field of genetic engineering, as it allows for precise editing of the genetic code.

Therapies

CRISPR Therapeutics is developing therapies across a broad range of diseases, including cancer, diabetes, and rare genetic disorders. The company's lead product candidate, CTX001, is being developed for the treatment of sickle cell disease and beta-thalassemia.

Clinical Trials

CRISPR Therapeutics has several therapies in clinical trials. The most advanced of these is CTX001, which is in Phase 1/2 clinical trials for the treatment of sickle cell disease and beta-thalassemia.

Partnerships

CRISPR Therapeutics has established partnerships with several pharmaceutical and biotechnology companies to accelerate the development of its therapies. These include collaborations with Vertex Pharmaceuticals and Bayer AG.

See Also

• Gene therapy
• Genetic engineering
• Biotechnology

References

<references />

External Links

• Official website

This article is a stub related to pharmacology. You can help WikiMD by expanding it!